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Abstract
Background: Stratified care is an up-to-date treatment approach suggested for patients with back pain in several
guidelines. A comprehensively studied stratification instrument is the STarT Back Tool (SBT). It was developed to
stratify patients with back pain into three subgroups, according to their risk of persistent disabling symptoms. The
primary aim was to analyse the disability differences in patients with back pain 12 months after inclusion according
to the subgroups determined at baseline using the German version of the SBT (STarT-G). Moreover, the potential to
improve prognosis for disability by adding further predictor variables, an analysis for differences in pain intensity
according to the STarT-Classification, and discriminative ability were investigated.
Methods: Data from the control group of a randomized controlled trial were analysed. Trial participants were
members of a private medical insurance with a minimum age of 18 and indicated as having persistent back pain.
Measurements were made for the risk of back pain chronification using the STarT-G, disability (as primary outcome)
and back pain intensity with the Chronic Pain Grade Scale (CPGS), health-related quality of life with the SF-12,
psychological distress with the Patient Health Questionnaire-4 (PHQ-4) and physical activity. Analysis of variance
(ANOVA), multiple linear regression, and area under the curve (AUC) analysis were conducted.
Results: The mean age of the 294 participants was 53.5 (SD 8.7) years, and 38% were female. The ANOVA for
disability and pain showed significant differences (p < 0.01) among the risk groups at 12 months. Post hoc Tukey
tests revealed significant differences among all three risk groups for every comparison for both outcomes. AUC for
STarT-G’s ability to discriminate reference standard ‘cases’ for chronic pain status at 12 months was 0.79. A
prognostic model including the STarT-Classification, the variables global health, and disability at baseline explained
45% of the variance in disability at 12 months.
Conclusions: Disability differences in patients with back pain after a period of 12 months are in accordance with
the subgroups determined using the STarT-G at baseline. Results should be confirmed in a study developed with
the primary aim to investigate those differences.
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Background
Back pain is one of the most prevalent symptoms en-
countered in primary care [1]. Its treatment is challen-
ging for primary care practitioners, such as
physiotherapists or general practitioners [2, 3]. It has
been discussed that determining the prognosis of back
pain is a priority for research and practice and may have
the potential to supersede diagnosis in its relevance [4].
For the purpose of prediction, several risk factors were
identified and differentiated as being modifiable (e.g.
psychological factors) or non-modifiable (e.g. pain his-
tory) [5–7]. Despite this knowledge, and although plan-
ning of treatment on such a basis seems ineffective,
prediction in clinical practice mainly relies on experience
and clinical judgement [1, 8].
Several prognosis-based approaches to subgroup pa-
tients with back pain have been developed [9]. One
which has demonstrated feasibility, clinical applicabil-
ity and cost-effectiveness is the STarT Back Approach
(STarT = Subgroups for Targeted Treatment) [10, 11].
To establish the prognosis of an unfavourable treat-
ment outcome for patients with back pain, biomedical
and modifiable psychosocial factors are determined
using the STarT Back Tool (SBT) [6]. With nine
items and mainly dichotomous answer categories, it is
easy to complete [6] (http://www.keele.ac.uk/sbst/
startbacktool/downloads/), and its utilisation is recom-
mended by national and international guidelines [12–
14]. Evaluation of the tool results in a biopsychosocial
total score and a sub-score focusing on psychosocial
constructs. A classification comprised of low-,
medium- and high-risk subgroups can be derived. For
groups at higher risk more severe disability is ex-
pected over time [6].
The SBT was originally developed in the UK [6]. Fol-
lowing an internationally agreed upon process, it was
cross-culturally adapted for German-speaking countries,
and several important psychometric properties were ex-
amined [15–17]. The German version is called STarT-G
[17]. Although the properties are not in total agreement
with those of the original version, they can be consid-
ered acceptable to good [16, 17]. Predictive ability has
been investigated internationally in a few studies, but
not for the German version [18–20].
The SBT was specifically developed for primary care
and supports physicians and therapists in the clinical
decision-making process. In addition to the advantage
of better quality of care, in the sense of a more
patient-oriented approach, it entails possibilities for
cost savings, and, as a result of the utilisation of the
tool, a reduction of unnecessary treatment may lead
to a reduced burden on the patient [10, 11, 21]. In
addition to its main area of application in clinical
practice, the tool could be used by stakeholders such
as health insurances to provide clients with better tar-
geted suggestions for prevention. A corresponding
programme called ‘initiative.rücken’ (‘back.initiative’)
was developed by a German private health insurance
company. It includes treatment by an interdisciplinary
network of therapists, and individual coaching by
phone is offered. An evaluation study was planned in
parallel with the implementation of this proactive in-
tegrated treatment programme, and among other in-
struments, the STarT-G was applied. However, since
the predictive ability of the German version has yet
to be established, the STarT-Classification was only
used for the purpose of description and not to derive
treatment recommendations [22].
The primary aim of the a priori planned analysis of
data from a pragmatic trial in health services research
was to analyse the disability differences in patients with
back pain 12months after inclusion, according to the
subgroups determined at baseline using the STarT-G.
Moreover, several secondary aims were set out. The po-
tential for improving prognosis for disability by adding
further psychosocial and lifestyle variables was investi-
gated. It was analysed whether the patients’ pain inten-
sity 12 months after inclusion differs in accordance with
the subgroups determined at baseline, and the properties
for discriminative ability and floor and ceiling effects
were determined.
Methods
Baseline and 12-month follow-up data of a Zelen ran-
domized controlled trial (RCT) conducted in 2015 to
evaluate the efficacy of a health programme for per-
sistent back pain were analysed. Participants of the
RCT were members of a German private medical in-
surance with a minimum age of 18 and with back
pain persisting for a period of more than 3 months.
For case identification, at least two entries, according
to ICD-10 codes M40–M54, had to be given in the
insurance database. Additionally, one case of tempor-
ary work disability in the previous 12 months was due
to ICD codes M40–M54, two opioid prescriptions or
data for other specified diagnoses. Inclusion and ex-
clusion criteria can be found in Table 1 (for an ex-
tended version with category names, see Appendix 1).
A random sample of eligible insured persons was ran-
domly allocated to the trial groups prior to their giv-
ing consent. The analysed data included in this study
came from those allocated to the control group, and
those people were invited to participate in a survey
dealing with persistent back pain while receiving
usual care. In this context, ‘usual care’ indicates that
patients received care at the behest of their treating
general practitioner or specialist, and the investigators
had no influence on the treatment. All persons who
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gave written informed consent received online ques-
tionnaires at baseline and again at 12 months after in-
clusion. Ethical approval for the trial was granted by
the Ethics Committee of the University of Luebeck
(registration ID: 14/249). Analysing the properties of
the STarT-G was planned at the same time as the de-
velopment of the primary RCT, which is described in
more detail in Hüppe et al. [13].
The investigated instrument is the STarT-G. It con-
sists of nine items and is used to determine an indi-
vidual’s prognosis related to disability. The first four
items relate to biomedical factors and the remaining
five identify modifiable psychosocial risk factors [6,
19]. A total-score ranging from 0 to 9 points and a
sub-score for the psychosocial risk factors ranging
from 0 to 5 points were calculated. Patients were
then allocated to one of three prognostic groups
using established scoring cut-offs (low-risk: total
score ≤ 3 points; medium-risk: total score > 3 and
sub-score < 4 points; high-risk: sub-score ≥ 4 points).
Disability and back pain intensity were measured
using the Chronic Pain Grade Scale (CPGS). The
CPGS disability score served as the patient’s primary
outcome (CPGS-DS). It shows back-pain-related dis-
ability, determined by the amount the pain interfered
with daily, social and work activities and ranges from
0 to 100, with higher scores indicating more disability
[23, 24]. Additionally, health-related quality of life,
psychological distress and physical activity were mea-
sured. For this purpose, the Short-Form-12 Physical
and Mental Health Summary Scales (SF-12; range 0
to 100, higher score indicating better health) [25], the
Patient Health Questionnaire-4 (PHQ-4; 0 to 12
points, higher score indicating more severe psycho-
logical distress) [26] and activity-specific items
according to DEGS1 were used (dichotomized into ra-
ther inactive = 0, rather active = 1; for details see [27]).
Statistics
Descriptive statistics were calculated to characterize the
study population, and completeness of follow-up data
was stated. To address the primary objective of the
analysis, an ANOVA using the STarT-Classification as a
grouping variable and the CPGS-DS at 12 months as the
outcome variable was conducted [19, 23]. Tukey tests
were done post hoc to analyse the mean differences
among the three subgroups. Deviation measures (SD)
were reported to estimate the variability of disability
within the risk groups at 12 months. This procedure,
without the inclusion of covariates such as age or other
scores, was chosen as the primary approach because the
9-item STarT-G is simple, allowing for use in clinical
practice as a single predictive instrument.
While the SBT comprises only modifiable risk factors,
the literature states that inclusion of other factors could
improve prediction [20, 28]. Therefore, the potential to
improve prognoses for disability by adding further vari-
ables was investigated as a secondary approach. This
was only done for our primary outcome disability at 12
months based on the CPGS-DS as the outcome variable.
The procedure encompassed two main steps. First, uni-
variate linear regression analyses were carried out to
check for, at least, a minimal dependence. Considered
were disability at baseline, depression/anxiety based on
the PHQ-4, patient self-prognosis for workability, phys-
ical activity and global health. All these variables were
derived from the survey. STarT-Classification was in-
cluded as two dummy coded variables, medium and high
risk (patients with a medium and high risk coded as 1
respectively), in each case against the other two groups
(coded as 0). Patients with a low-risk were used as the
reference, being 0 in both dummy variables. For the vari-
ables to pass to step two (multiple linear regression ana-
lysis), a result of p ≤ 0.2 was necessary from univariate
analysis. For the multiple linear regression analysis, the
variables were included block-wise. First, the
STarT-Classification variables were included to deter-
mine the variance explained by the STarT-G. Second,
the covariates from the univariate analyses were in-
cluded before the final model was determined by apply-
ing a backward stepwise method.
For pain intensity at 12 months as the outcome vari-
able, an ANOVA was carried out as described for the
primary objective.
Table 1 In- and exclusion criteria checked in the insurance database
Inclusion - Age ≥ 18 years
- ≥ 2 cases of settlement data due to ICD codes M40-M54
- Additionally, one of the following three
- ≥ 1 cases of temporary work disability in the past 12 months due to ICD codes M40-M54,
- two opioid prescriptions or
- settlement data due to one of the following ICD-10 codes: F32.-, F33.-, F34.1–34.9, F38.-, F41.2, F43.2, F45.4, F48.0, F54, F62.8
Exclusion - Care level II or III (long-term care insurance act, SGBXI)
- ICD codes in the past 12 months (settlement data ≥2 for the same diagnosis or≥ 5 different)
- B16.-16.9, B17.1, B20–24, D00-D09.9, F00.-F09, F10.0–19.9 (not F17.0–9), F20.-F29, F30.-F30.9, F31.-F31.9, F42.-F42.9, F60.-F60.9,
G00–09, G10, G13.-G13.8, G23.-G23.9, G30.-32.8, G36.-G36.9, G37.9, G92, G93.-G93.9, H54.0, H91.3, I64, K74.-K74.6, N18.0,
N18.3–4, N18.9, R54
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To quantify discriminative ability for patients with dif-
ferent disability and depression/anxiety statuses based
on the PHQ-4, receiver operating characteristic (ROC)
curves with area under the curve (AUC) and 95% confi-
dence interval (CI) for CPGS against STarT-G total score
and PHQ-4 against STarT-G sub-score were computed
for baseline and at 12 months. The CPGS was calculated
following the standards given by von Korff et al. [23]. To
compute ROC curves, a dichotomous reference standard
is needed. To define reference standard ‘cases’, the
GCPS-categories established by von Korff et al. [23]
were used: Grades 0, I and II (low disability) versus
Grades III and IV (high disability cases). For definition
of PHQ-4 cases, the predefined groups of none and mild
versus moderate and strong burden were combined. Ad-
jectives that can be used to describe AUC values have
been proposed by Hosmer and Lemeshow with an AUC
= 0.5 indicating ‘no discrimination’, 0.7 to < 0.8 as ‘ac-
ceptable discrimination’, 0.8 to 0.9 as ‘excellent discrim-
ination’ and > 0.9 as ‘outstanding discrimination’ [29].
Additional information on the relationships among the
instruments was acquired by calculating Spearman correl-
ation coefficients for the STarT-G total and sub-scores
against the CGPS-DS, the PHQ-4-score and the SF-12
sub-scores for physical function and mental health, based
on the original metrically scaled variables. As stated for
the original version, higher correlations were expected for
the total score versus the physical aspects and for the
sub-score versus the psychological aspects [6].
Floor and ceiling effects were defined as present if
more than 15% of the responders achieved the lowest or
highest possible STarT-G total score [30].
Statistical tests were two-sided, and a significance level
of alpha = 5% was used, unless otherwise stated. The
analyses were performed using IBM SPSS Statistics 25.0
(IBM, Armonk, NY, USA). Figures were produced using
the R language and environment for statistical comput-
ing software version 3.4.1 [31].
Results
From the database of the private medical insurance
company, a random sample of 1499 eligible members
was randomly allocated to the control group and invited
to take part in a survey. Of those, 294 gave informed
consent and answered the baseline questionnaire, and
243 (82.7%) participated in the 12-month follow-up. The
mean age of participants was 53.5 (SD 8.7) years, and
38% were female. There were no significant differences
for age (p = 0.56) and gender (p = 0.12) between re-
sponders and non-responders. The mean STarT-G total
and sub-scores were 3.2 (SD 2.3) and 1.3 (SD 1.4), re-
spectively. The risk group distribution was 62.6% for
low, 27.6% for medium and 9.9% for high risk. Further
baseline values are given in Table 2.
The ANOVA for disability at 12 months indicated sig-
nificant differences (dftotal = 242, F = 51.7, p < 0.001)
among the groups (Fig. 1). Post hoc Tukey tests revealed
Table 2 Characteristics of the study population
Mean age in years (SD) n 53.5 (8.65) 293
Gender female %, n 38.1 112
Total 294
Mean Body-Mass-Index in kg/m2 (SD) n 27.2 (4.91) 293
Education %, n
up to 9 years 12.8 37
10 to 11 years 41.3 119
12 to 13 years 45.8 132
Total 288
Physically active per week %, n
Never 14.6 43
1 day 16.7 49
≥ 2 days 68.7 202
Total 294
Mean (SD) pain intensity (0–100) n 44.7 (21.24) 294
Mean (SD) CPGS-DS (0–100) n 36.8 (24.63) 294
CPGS %, n
chronic pain grade low disability (Stadium 0 - II) 58.5 172
chronic pain grade high disability (Stadium III + IV) 41.5 122
Total 294
SF-12 Physical Health, mean (SD) n 40.3 (11.45) 294
SF-12 Mental Health, mean (SD) n 44.5 (12.06) 294
General health n, %
less good/poor 38.1 112
good/excellent 61.9 182
Total 294
PHQ-4, mean (SD) n 3.3(2.75) 294
Working until pension (patient self-prognosis) %, n
sure/probably yes 56.02 149
unsure/probably no/certainly not 43.98 117
Total 266
Mean STarT-G total (SD) n 3.2 (2.29) 294
Mean STarT-G subscale (SD) n 1.3 (1.42) 294
STarT risk group %, n
Low risk 62.6 184
Medium risk 27.6 81
High risk 9.9 29
Total 294
CPGS Chronic Pain Grade Scale, DS disability score, SF-12 Short Form-12 Health
Survey, STarT Subgroups for Targeted Treatment Back Tool, STarT-G German
version of the STarT-Back Tool, PHQ-4 Patient Health Questionnaire (4
items). n = 294
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significant differences among all three risk groups for
every comparison (Table 3).
For the multivariable regression analysis, four vari-
ables were adopted along with the STarT-Classification
variables. Following the univariate step the p-values of
the variables patient self-prognosis for workability, glo-
bal health, disability at baseline and depression/anxiety,
satisfied the set threshold of p ≤ 0.2 (Table 4). As a re-
sult of the first block of the regression analysis with
only the STarT-Classification variables included, 28% of
the variance in disability at 12 months was explained
(adjusted R2). During the backward stepwise procedure,
subjective work prognosis and depression/anxiety were ex-
cluded. The final model included the STarT-Classification
variables, global health and disability at baseline (Table 5).
ANOVA for the final regression model resulted in p < 0.001.
The model predicted 45% of the variance in disability at 12
months (adjusted R2). The resulting model reads as follows:
Disability at 12months (CPGS-DS) = -5.61 + 5.59*STarT
group medium risk + 14.26*STarT group high risk +
0.41*Disability at baseline + 6.44*General health. Semi-partial
correlation coefficients ranged from 0.08 to 0.28.
The ANOVA for pain intensity at 12 months indicated
significant differences between the risk groups (dftotal =
242, F = 50.3, p < 0.001). Post hoc Tukey tests revealed
significant differences for every comparison among all
three risk groups (Table 3).
The AUC for STarT-G’s ability to discriminate refer-
ence standard ‘cases’ at baseline/12 months was 0.80
(95% CI 0.74, 0.85)/0.79 (95% CI 0.73, 0.85) for disability
and 0.83 (95% CI 0.78, 0.88)/0.76 (95% CI 0.69, 0.84) for
depression/anxiety, indicating acceptable to excellent
discrimination (Fig. 2a to d).
Spearman coefficients for the STarT-G total and
sub-score versus CPGS-DS, SF-12 Physical Health,
SF-12 Mental Health and PHQ-4 scores are given in
Table 6 (for graphical relationships between the STarT-G
total score and CGPS-DS and between the STarT-G
sub-score and PHQ-4, see Appendix 2).
No floor or ceiling effects were found (8.2%, n = 24 pa-
tients with 0 points; 2.0%, n = 6 patients with 9 points).
Discussion
In this study, data from nearly 300 patients were analysed.
Used on its own, the STarT-Classification was of great value
to predict differences in back-related disability 12months
Fig. 1 Boxplots for STarT-G subgroups low-, medium- and high-risk groups versus CPGS at 12 months. CPGS = Chronic Pain Grade Scale, DS =
disability score, STarT-G = German version of the STarT-Back Tool. n = 243
Table 3 Post hoc Tukey analyses disability and pain intensity at
12 months
Mean (SD) Mean Difference p
CPGS-DS at 12 months/ STarT group
Low-Risk 24.10 (20.06) 21.86 < 0.001
Medium-Risk 45.96 (22.72)
Medium-Risk 45.96 (22.72) 17.10 0.002
High-Risk 63.06 (19.83)
Low-Risk 24.10 (20.06) 38.96 < 0.001
High-Risk 63.06 (19.83)
Pain intensity at 12 months/ STarT group
Low-Risk 35.21 (19.06) 19.74 < 0.001
Medium-Risk 54.95 (16.07)
Medium-Risk 54.95 (16.07) 12.41 0.012
High-Risk 67.36 (16.59)
Low-Risk 35.21 (19.06) 32.15 < 0.001
High-Risk 67.36 (16.59)
CPGS Chronic Pain Grade Scale, DS disability score, STarT Subgroups for
Targeted Treatment Back Tool
n = 243
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after recruitment. By including additional variables in a
prognostic model, it was possible to explain nearly half of
the variance in disability at 12months. Moreover, proper-
ties already determined in previous studies were confirmed,
in part, with even higher coefficient values in the present
sample [18, 19].
Primary users of the SBT are physiotherapists and pri-
mary care physicians [2, 3, 10]. In addition, utilisation of
the tool by health insurance companies might have the
potential for a more targeted disbursement of resources.
Knowledge from previous research about the psychomet-
ric properties of the tool have been given, although not for
its prognostic ability [18, 19]. Since such information is
vital for clinicians [20], as well as for institutions, the given
results have the potential to foster effective implementa-
tion. For health insurance companies, the presented ana-
lyses indicate possibilities for utilization of the instrument
in their field.
Comparing the risk group distribution from the
present study, which had many low-risk and a few
high-risk patients, with those from other studies con-
ducted in German-speaking countries, differences can
be observed [6, 18, 19]. Various factors might influ-
ence the distribution. One might be the time point of
administration [32–34]. Beneciuk et al. determined
that more than three-quarters of high-risk patients
changed categories after 4 weeks [33]. An alternative
explanation for the differences in risk group distribu-
tion might be the recruitment strategy used for the
study to provide the data analysed in this article. Par-
ticipants were selected from the database of a health
insurance and not in routine care.
The strength of the SBT is that the prognosis can be de-
rived in clinical practice without gathering covariates. This
approach worked well in this study’s chosen sample and
is, therefore, in line with both the results from the devel-
opers’ external sample and another study including pa-
tients with chronic complaints [6, 21]. In contrast,
Kongsted et al. used the SBT without covariates and de-
scribed low accuracies for the Danish version of the tool
[8]. In the present study, multiple linear regression ana-
lysis was only used as a secondary approach, but inclusion
of covariates considerably improved prediction leading to
an explanation of nearly half of the variance. Toh et al.
stated that covariates were needed to obtain a better pre-
dictive model for pain scores at follow-up, whereas Medei-
ros et al. directly chose to include covariates, resulting in
no predictive capability when using the baseline
STarT-Classification [28, 35]. Consequently, the effect of
including covariates needs further examination, while also
remembering that the aim is to keep prediction as simple
as possible for practice by focusing on modifiable factors.
Table 4 Predictors for disability (CPGS-DS) at 12 months: Results of univariate Regression Analysis
Unstandardized Coefficients
Prognostic factor B Beta p CI for B low, high
STarT group medium risk 16.58 0.30 < 0.001 9.85, 23.31
STarT group high risk 32.37 0.39 < 0.001 22.69, 42.05
CPGS-DS baseline 0.69 0.68 < 0.001 0.59, 0.78
PHQ-4 3.27 0.38 < 0.001 2.26, 4.29
Subjective prognosis work 7.77 0.40 < 0.001 5.38, 10.15
General health 17.29 0.55 < 0.001 13.99, 20.61
Physical activity 1.00 0.70 0.25 −0.72, 2.72
CI 95% confidence interval, CPGS Chronic Pain Grade Scale, DS disability score, STarT Subgroups for Targeted Treatment Back Tool, PHQ-4 Patient Health
Questionnaire (4 items), italicised indicating p > 0.2
Table 5 Predictors for disability (CPGS-DS) at 12 months: Results of the finale modle from multiple linear regression analysis
Unstandardised Coefficients
B Beta p CI for B low, high Semi-part
(Constant) −5.61 0.320 −16.68, 5.47
Medium-risk STarT group 5.59 0.10 0.098 −1.05, 12.23 0.08
High-risk STarT group 14.26 0.17 0.004 4.50, 24.02 0.14
CPGS-DS baseline 0.41 0.40 < 0.001 0.26, 0.55 0.28
General health 6.44 0.21 0.001 2.51, 10.37 0.16
CI 95% confidence interval, CPGS Chronic Pain Grade Scale, DS disability score, STarT Subgroups for Targeted Treatment Back Tool, Semi-part
semi-partial correlation
n = 219
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A consideration of the results from the regression ana-
lysis revealed that other factors, as well as the
STarT-classification, provided predictive information;
here, these were disability at baseline and general health.
The relevance of baseline scores is a common
phenomenon in the literature [7, 32, 33] and is underlined
by the determined semi-partial correlation coefficient in
this study. In regard to general health, one simple item
was identified which should be kept in mind for future
predictive models. Also, the result indicating that the
baseline score is a prominent predictor agrees with results
from other studies [7, 32]. In the presented analysis, the
STarT-Classification was used. Other researchers discuss
the potential of the sub-score which might lead to differ-
ent conclusions [28]. To improve predictive ability,
different researchers have suggested a repeated application
of the SBT, e.g. pre- and post-treatment, including the no-
tion of change of the STarT risk group [33, 35].
Our work focused on disability being one of the core
domains for patients with back pain [36], and pain in-
tensity was chosen as a secondary outcome. This is in
line with the strength of the SBT [20], but it has to be
kept in mind, for example, when working with patients
with pain as the major complaint, since predictive fac-
tors may differ between pain and disability [32].
The correlations determined in the presented analyses
also showed similarities to results for the original version of
the SBT. Stronger correlations were determined between
the total score and physical measures and the sub-scores
and psychological measures rather than vice versa [6].
Fig. 2 a to d Receiver operating characteristic curves. CPGS versus STarT-G total score and PHQ-4 versus STarT-G sub-score (baseline and 12
months). CPGS = Chronic Pain Grade Scale (dichotomized: Grade 0,I and II versus Grade III and IV), STarT-G = German version of the STarT-Back
Tool, PHQ4 = Patient Health Questionnaire (4 items, dichotomized: none and mild versus moderate and severe psychological distress), 12 M = at
12months. nA = 294, nB = 294, nC = 242, nD = 243
Table 6 Correlation coefficients
CPGS-DS PHQ-4 SF-12 Physical Health SF-12 Mental Health
START-G total score rho 0.70 0.53 −0.65 −0.42
START-G sub-score rho 0.61 0.58 −0.51 −0.51
Rho Spearman’s rho, CPGS Chronic Pain Grade Scale, DS disability score, STarT-G German version of the STarT-Back Tool, PHQ-4 Patient Health Questionnaire
(4 items)
n = 294, all correlations are significant; p < 0.001 in each case (two-tailed)
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The STarT Back approach depends on the SBT. To
conduct stratified care, therapists should be upskilled
through a training course in order to successfully ad-
dress the complex needs of high-risk patients through
the delivery of ‘psychologically informed physiotherapy’
[37]. Evidence suggests that physiotherapists trained in
this manner are effective in managing around 85% of
this high-risk complex patient group, but training might
still be helpful to encourage therapists [38–42].
Strengths and weaknesses
For this article, data from a control group of an RCT were
analysed. In the literature, several advantages and disad-
vantages are described for such a proceeding [43]. An im-
portant aspect that reduced information bias was that the
analysis of the STarT-G properties was intended from the
design period forward: the analyses were planned by SK
and KH before receiving access to the data.
The questionnaires chosen for the study were compre-
hensively validated, and established cut-offs were available
[26, 45, 46]. On the other hand, the study sample was spe-
cifically selected. Only patients from one private health in-
surance were included, and, although approximately only
10% of the population are similarly insured [47], with
nearly 350,000 customers, the company is large enough to
represent a relevant group of people. Fewer than a fifth of
the patients were lost to follow-up. This does not exceed
the benchmark of 30% set for long term follow-up by the
Cochrane Back and Neck Group. However, since the
benchmark is set arbitrary, bias is still possible [48].
Patients with nonspecific complaints is the group which
the SBT targets. In the present study, inclusion of the pa-
tients was conducted on the grounds of a search in the
database of the insurance company using ICD-codes.
Since a comprehensive range of diagnosis was undertaken
by using codes M40 to M54, the possibility that patients
with serious complaints had been included cannot be dis-
counted. Nevertheless, inclusion of the patients for the de-
velopment study of the SBT was also based on a
computerized search. In the latter study, as in ours, red
flag diagnoses, such as cancer, were defined as exclusion
criteria [6, 44]. Despite the possibility of a heterogeneous
sample being analysed, it is notable that the tool still dem-
onstrated acceptable properties.
In various studies on the SBT, missing data were
identified as a challenge when using the instrument
in research. For approximately up to one-tenth of the
patients in this previous work, it was not possible to
determine the risk group [19, 49]. In the present
study, it was possible to identify the risk group for all
participants because there were no missing values,
simply because the online tool used did not accept
unanswered questions.
Conclusions
Differences in the disability of patients with back pain after
a period of 12months agree with the subgroup classifica-
tion determined by using the STarT-G at baseline. By add-
ing prognostic variables to the STarT-Classification in a
prognostic model, it is possible to explain nearly half of the
variance observed in disability at the 12-month follow-up.
Considering this information, the instrument can be used
more purposefully by practitioners. Further studies to
examine the predictive ability and timing of the application
of the STarT-G in clinical practice and when it would be
best for insurers to implement it should be conducted.
Appendix 1
Table 7 In- and exclusion criteria checked in the insurance
database, version including ICD category names
Inclusion - Age ≥ 18 years
- ≥ 2 cases of settlement data due to ICD codes
M40-M54 (Dorsopathies)
- Additionally one of the following three
- ≥ 1 cases of temporary work disability in the past
12 months due to ICD codes M40-M54,
- two opioid prescriptions or
- settlement data due to one of the following ICD-10 codes:
F32.- (Depressive episode), F33.- (Recurrent depressive
disorder), F34.1-34.9 (Dysthymia, other and unspecified
persistent mood [affective] disorders), F38.- (Other mood
[affective] disorders), F41.2 (Mixed anxiety and depressive
disorder), F43.2 (Adjustment disorders), F45.4 (Persistent
somatoform pain disorder), F48.0 (Other neurotic disorders),
F54 (Psychological and behavioural factors associated with
disorders or diseases classified elsewhere), F62.8 (Other
enduring personality changes)
Exclusion - Care level II or III (long-term care insurance act, SGBXI)
- ICD codes in the past 12 month (settlement data ≥ 2
for the same diagnosis or ≥ 5 different)
- B16.-16.9 (Acute hepatitis B), B17.1 (Acute hepatitis C),
B20-24 (Human immunodeficiency virus [HIV] disease),
D00-D09.9 (In situ neoplasms), F00.-F09 (Organic, including
symptomatic, mental disorders), F10.0-19.9 (Mental and
behavioural disorders due to psychoactive substance use,
not F17.0- 9), F20.-F29 (Schizophrenia, schizotypal and
delusional disorders), F30.-F30.9 (Manic episode), F31.-F31.9
(Bipolar affective disorder), F42.-F42.9 (Obsessive-compulsive
disorder), F60.-F60.9 (Specific personality disorders), G00-09
(Inflammatory diseases of the central nervous system), G10
(Huntington disease), G13.-G13.8 (Systemic atrophies
primarily affecting central nervous system in diseases
classified elsewhere), G23.-G23.9 (Other degenerative
diseases of basal ganglia), G30.-32.8 (Other degenerative
diseases of the nervous system), G36.-G36.9 (Other acute
disseminated demyelination), G37.9 (Demyelinating disease
of central nervous system, unspecified), G92 (Demyelinating
disease of central nervous system, unspecified), G93.-G93.9
(Other disorders of brain), H54.0 (Visual impairment
including blindness (binocular or monocular)), H91.3 (Deaf
mutism, not elsewhere classified), I64 (Stroke, not specified
as haemorrhage or infarction), K74.-K74.6 (Fibrosis and
cirrhosis of liver), N18.0 (Chronic kidney disease), N18.3-4
(Chronic kidney disease, stage 3/stage 4), N18.9 (Chronic
kidney disease, unspecified), R54 (Senility)
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